Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 2, 2026, 7:45 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2617–2640 of 10,818 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Developmental Defect Clear all
Completed Phase 3 Interventional Results available

Phase 3 Triiodothyronine Supplementation for Infants After Cardiopulmonary Bypass

NCT02320669
View directory record Official record
Conditions
Congenital Heart Defects
Interventions
Triostat, Placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
Up to 5 Months
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
3
States / cities
Los Angeles, California • Palo Alto, California • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 9, 2024 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting Phase 4 Interventional

Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study

NCT05548283
View directory record Official record
Conditions
Cystic Fibrosis, Cystic Fibrosis Pulmonary Exacerbation
Interventions
Beta-lactam antibiotic, Aminoglycoside
Drug
Lead sponsor
Chris Goss
Other
Eligibility
6 Years and older
Enrollment
730 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
59
States / cities
Birmingham, Alabama • Tucson, Arizona • La Jolla, California + 49 more
Source: ClinicalTrials.gov public record
Updated Jul 8, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 3 Interventional Results available

A Study of Lumacaftor in Combination With Ivacaftor in Cystic Fibrosis Subjects Aged 12 Years and Older Who Are Homozygous for the F508del-CFTR Mutation

NCT01807923
View directory record Official record
Conditions
Cystic Fibrosis, Homozygous for the F508del CFTR Mutation
Interventions
Lumacaftor Plus Ivacaftor Combination, Ivacaftor, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
12 Years and older
Enrollment
559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
48
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 45 more
Source: ClinicalTrials.gov public record
Updated Aug 31, 2015 · Synced Nov 2, 2026, 7:45 PM EST
Completed No phase listed Observational

A Natural History of Late Onset Tay-Sachs Disease

NCT02851862
View directory record Official record
Conditions
GM2 Gangliosidosis
Interventions
Not listed
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
7 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting Not applicable Interventional

Remote Delivery of a Mindfulness-based Intervention for Tics

NCT06408662
View directory record Official record
Conditions
Tourette Syndrome, Tourette's Disorder, Chronic Motor Tic Disorder, Chronic Vocal Tic Disorder, Persistent Motor Tic Disorder, Persistent Vocal Tic Disorder, Persistent Tic Disorder, Tic Disorders
Interventions
mindfulness-based intervention for tics (MBIT), psychoeducation with relaxation and supportive therapy (PRST)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 2 Interventional Results available

Study of LAU-7b in the Treatment of Cystic Fibrosis in Adults

NCT03265288
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
LAU-7b, Placebo oral capsule
Drug
Lead sponsor
Laurent Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
27
States / cities
Long Beach, California • Los Angeles, California • Sacramento, California + 24 more
Source: ClinicalTrials.gov public record
Updated Oct 9, 2024 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 2 Interventional Results available

L-Glutamine Therapy for Sickle Cell Anemia and Sickle ß0 Thalassemia

NCT00125788
View directory record Official record
Conditions
Sickle Cell Anemia, Thalassemia
Interventions
L-glutamine, Placebo
Drug
Lead sponsor
Emmaus Medical, Inc.
Industry
Eligibility
5 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
5
States / cities
Bellflower, California • Torrance, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2021 · Synced Nov 2, 2026, 7:45 PM EST
Completed No phase listed Observational

Beacon Tip Sizing Catheter and Slip-Cath Beacon Tip Catheter Study

NCT06986954
View directory record Official record
Conditions
Stenosis, Bleed Intracranial, Stroke, TIA, Vascular Malformation, Pseudoaneurysm
Interventions
Beacon Tip Catheters
Device
Lead sponsor
Cook Research Incorporated
Industry
Eligibility
Not listed
Enrollment
816 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Darien, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 1Phase 2 Interventional Results available

Clofarabine and Cytarabine in Treating Older Patients With AML or High-Risk MDS

NCT00839982
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Myelodysplastic Syndrome With Isolated Del(5q), Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia
Interventions
clofarabine, cytarabine
Drug
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
60 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Nov 2, 2026, 7:45 PM EST
Withdrawn Not applicable Interventional

Point-Of-Care Testing for Congenital Syphilis in Mothers and Newborns

NCT03814096
View directory record Official record
Conditions
Maternal Syphilis During Pregnancy - Baby Not Yet Delivered, Congenital Syphilis
Interventions
Syphilis Health Check POC-test (Diagnostics Direct LLC, NJ)
Diagnostic Test
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
2
States / cities
San Jose, California • Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 13, 2019 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 1 Interventional

Cyclophosphamide Plus Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

NCT00006042
View directory record Official record
Conditions
Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
filgrastim, cyclophosphamide, fludarabine phosphate, mycophenolate mofetil, tacrolimus, allogeneic bone marrow transplantation, radiation therapy
Biological · Drug · Procedure + 1 more
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
Up to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1999
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 10, 2010 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 1 Interventional

A Pharmacokinetic and Tolerance Study of Oral Ganciclovir in HIV-Infected Children With Asymptomatic Cytomegalovirus Infection and Low CD4 Cell Counts or Quiescent Cytomegalovirus Disease

NCT00000805
View directory record Official record
Conditions
Cytomegalovirus Infections, HIV Infections
Interventions
Ganciclovir
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
14 Days to 20 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
18
States / cities
Los Angeles, California • Oakland, California • San Diego, California + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting No phase listed Observational

Uncovering Genes Behind Cartilage Tumors and Vascular Anomalies Using Genomic Sequencing

NCT06749366
View directory record Official record
Conditions
Enchondromatosis
Interventions
Not listed
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
NIH
Eligibility
2 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Defining the Skin and Blood Biomarkers of Pediatric Atopic Dermatitis

NCT01782703
View directory record Official record
Conditions
Atopic Dermatitis, Eczema
Interventions
Not listed
Lead sponsor
Northwestern University
Other
Eligibility
0 Months to 17 Years
Enrollment
505 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2027
U.S. locations
4
States / cities
Chicago, Illinois • Northbrook, Illinois • New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 27, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting No phase listed Observational

Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program

NCT05040373
View directory record Official record
Conditions
Hereditary Transthyretin-mediated (hATTR) Amyloidosis, Polyneuropathy
Interventions
Not listed
Lead sponsor
Alnylam Pharmaceuticals
Industry
Eligibility
Female only
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Withdrawn Phase 1 Interventional

Aberrations in Carnitine Homeostasis in Congenital Heart Disease With Increased Pulmonary Blood Flow

NCT01825369
View directory record Official record
Conditions
Heart Septal Defects, Ventricular, Atrioventricular Septal Defect
Interventions
IV L-carnitine
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
2 Months to 12 Months
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated May 6, 2020 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 2Phase 3 Interventional

To Study the Efficacy & Safety of Oral NA-921 (Bionetide) in Girls and Women with Rett Syndrome

NCT06849973
View directory record Official record
Conditions
Rett Syndrome
Interventions
Drug: Bionetide, Placebo
Drug
Lead sponsor
Biomed Industries, Inc.
Industry
Eligibility
5 Years to 20 Years · Female only
Enrollment
187 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
12
States / cities
La Jolla, California • Los Angeles, California • Sacramento, California + 9 more
Source: ClinicalTrials.gov public record
Updated Feb 27, 2025 · Synced Nov 2, 2026, 7:45 PM EST
Completed Not applicable Interventional Results available

Tourette Syndrome Deep Brain Stimulation

NCT02056873
View directory record Official record
Conditions
Tourette Syndrome
Interventions
Continuous DBS, Responsive Brain Stimulation (RBS Setting)
Device
Lead sponsor
University of Florida
Other
Eligibility
21 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2023
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 2Phase 3 Interventional

Arimidex Multicenter Trial in Growth Hormone (GH) Deficient Boys

NCT00133354
View directory record Official record
Conditions
Hypopituitarism
Interventions
Arimidex (Anastrozole), Placebo, Growth Hormone
Drug
Lead sponsor
Nemours Children's Clinic
Other
Eligibility
11 Years to 18 Years · Male only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2010
U.S. locations
1
States / cities
Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Nov 2, 2026, 7:45 PM EST
Completed No phase listed Observational

Autologous Fat Grafting of the Breast in Women With Post Lumpectomy Contour Defects

NCT02302196
View directory record Official record
Conditions
Cancer of the Breast, Anomaly of Breast
Interventions
Autologous Fat Grafting of the Breast, Control Arm
Procedure · Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older · Female only
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Clackamas, Oregon
Source: ClinicalTrials.gov public record
Updated Aug 20, 2021 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting Phase 2 Interventional

A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema

NCT07216027
View directory record Official record
Conditions
Atopic Dermatitis, Eczema, Atopic
Interventions
PF-08049820, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 64 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
17
States / cities
Phoenix, Arizona • Scottsdale, Arizona • Huntington Beach, California + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Recruiting Phase 2Phase 3 Interventional

A Study in Pediatric Participants With Congenital Adrenal Hyperplasia (Balance-CAH)

NCT07159841
View directory record Official record
Conditions
Congenital Adrenal Hyperplasia, Classic Congenital Adrenal Hyperplasia
Interventions
Atumelnant, Placebo
Drug
Lead sponsor
Crinetics Pharmaceuticals Inc.
Industry
Eligibility
1 Year to 17 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
10
States / cities
San Francisco, California • Chicago, Illinois • Boston, Massachusetts + 7 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2026 · Synced Nov 2, 2026, 7:45 PM EST
Completed Phase 3 Interventional Results available

Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity

NCT02664441
View directory record Official record
Conditions
Hypothalamic Obesity
Interventions
Exenatide, placebo
Drug
Lead sponsor
Seattle Children's Hospital
Other
Eligibility
10 Years to 25 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
3
States / cities
Minneapolis, Minnesota • Nashville, Tennessee • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated May 5, 2022 · Synced Nov 2, 2026, 7:45 PM EST
Completed No phase listed Observational

Down Syndrome Autonomic Nervous System Induction Bradycardia

NCT05120531
View directory record Official record
Conditions
Down Syndrome, Bradycardia
Interventions
Monitoring patients undergoing surgery to look for association between ANS activity and bradycardia
Other
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Month to 8 Years
Enrollment
195 participants
Timeline
2022 – 2023
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 15, 2023 · Synced Nov 2, 2026, 7:45 PM EST